Clinical Trials
Multiple clinical trials spanning Phase 1 through Phase 4 have evaluated colestipol hydrochloride for managing hypercholesterolemia, hyperlipidemia, coronary atherosclerosis, accelerated teriflunomide elimination, erythropoietic protoporphyria, and diarrhea mitigation in HER2-positive breast cancer patients. Sponsored by pharmaceutical corporations, government institutes, and academic medical centers, these studies maintain recruitment statuses ranging from completed to terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02400476 | COMPLETED | Early Stage HER2+ Breast Cancer |
Puma Biotechnology, Inc. |
2015-02 | PHASE2 |
| NCT02263547 | TERMINATED | Teriflunomide Elimination; Healthy Volunteers |
Derrick Scott Robertson |
2015-03 | PHASE1 |
| NCT02263547 | Terminated | Teriflunomide Elimination|Healthy Volunteers |
Derrick Scott Robertson|Genzyme a Sanofi Company|University of South Florida |
2015-03 | Phase 1 |
| NCT01422915 | COMPLETED | Erythropoietic Protoporphyria |
Brigham and Women's Hospital |
2011-05 | PHASE2; PHASE3 |
| NCT00203476 | COMPLETED | Hyperlipidemia; Hypercholesterolemia |
Tuscaloosa Research & Education Advancement Corporation |
2005-05 | PHASE4 |
| NCT00000512 | COMPLETED | Cardiovascular Diseases; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Ischemia |
University of Washington |
1984-01 | PHASE3 |
| NCT00000599 | COMPLETED | Arterial Occlusive Diseases; Cardiovascular Diseases; Carotid Artery Diseases; Cerebral Arteriosclerosis; Cerebrovascular Disorders; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Ischemia; Atherosclerosis |
National Heart, Lung, and Blood Institute (NHLBI) |
1980-06 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2022-05-06)
Check the
Colestipol Hydrochloride
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.